SAM CHUN DANG PHARM. CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 105,600 KRW | -0.94% |
|
+5.39% | +36.61% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 813,421 | 762,047 | 1,811,786 | 956,650 | 966,580 | 1,759,153 |
| Enterprise Value (EV) 1 | 751,527 | 686,190 | 1,736,895 | 906,166 | 956,922 | 1,720,034 |
| P/E ratio | 92.9 x | 73 x | -1,824 x | -57.8 x | 166 x | -167 x |
| Yield | 0.13% | 0.14% | - | - | - | - |
| Capitalization / Revenue | 5.09 x | 4.08 x | 10.9 x | 5.72 x | 5.45 x | 9.13 x |
| EV / Revenue | 4.7 x | 3.68 x | 10.4 x | 5.42 x | 5.4 x | 8.93 x |
| EV / EBITDA | 34.5 x | 21.6 x | 158 x | -106 x | 47.3 x | 95.6 x |
| EV / FCF | 297 x | 44.3 x | -117 x | -36.8 x | -27.3 x | -92.4 x |
| FCF Yield | 0.34% | 2.26% | -0.85% | -2.72% | -3.66% | -1.08% |
| Price to Book | 5.48 x | 4.83 x | 9.71 x | 5.49 x | 5.56 x | 7.98 x |
| Nbr of stocks (in thousands) | 21,406 | 21,406 | 22,068 | 22,068 | 22,068 | 22,757 |
| Reference price 2 | 38,000 | 35,600 | 82,100 | 43,350 | 43,800 | 77,300 |
| Announcement Date | 3/6/19 | 2/27/20 | 2/26/21 | 3/21/22 | 3/21/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 159,960 | 186,602 | 166,862 | 167,275 | 177,335 | 192,669 |
| EBITDA 1 | 21,803 | 31,702 | 10,992 | -8,548 | 20,220 | 17,990 |
| EBIT 1 | 15,500 | 25,210 | 4,306 | -15,289 | 12,569 | 9,560 |
| Operating Margin | 9.69% | 13.51% | 2.58% | -9.14% | 7.09% | 4.96% |
| Earnings before Tax (EBT) 1 | 14,461 | 19,317 | 16,581 | -19,549 | 8,920 | -4,549 |
| Net income 1 | 8,754 | 10,452 | -965.7 | -16,555 | 5,838 | -10,383 |
| Net margin | 5.47% | 5.6% | -0.58% | -9.9% | 3.29% | -5.39% |
| EPS 2 | 409.0 | 488.0 | -45.00 | -750.2 | 264.5 | -463.0 |
| Free Cash Flow 1 | 2,532 | 15,494 | -14,792 | -24,647 | -35,043 | -18,623 |
| FCF margin | 1.58% | 8.3% | -8.86% | -14.73% | -19.76% | -9.67% |
| FCF Conversion (EBITDA) | 11.62% | 48.87% | - | - | - | - |
| FCF Conversion (Net income) | 28.93% | 148.24% | - | - | - | - |
| Dividend per Share 2 | 50.00 | 50.00 | - | - | - | - |
| Announcement Date | 3/6/19 | 2/27/20 | 2/26/21 | 3/21/22 | 3/21/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 61,894 | 75,857 | 74,891 | 50,484 | 9,658 | 39,119 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 2,532 | 15,494 | -14,792 | -24,647 | -35,043 | -18,623 |
| ROE (net income / shareholders' equity) | 7.31% | 9.14% | 3.12% | -4.08% | 3.56% | -1.54% |
| ROA (Net income/ Total Assets) | 3.94% | 5.72% | 0.89% | -2.89% | 2.19% | 1.53% |
| Assets 1 | 221,992 | 182,853 | -108,944 | 572,625 | 266,493 | -678,432 |
| Book Value Per Share 2 | 6,938 | 7,375 | 8,457 | 7,889 | 7,873 | 9,689 |
| Cash Flow per Share 2 | 2,405 | 2,816 | 2,671 | 2,226 | 1,001 | 1,776 |
| Capex 1 | 11,552 | 6,594 | 8,679 | 14,882 | 16,531 | 6,766 |
| Capex / Sales | 7.22% | 3.53% | 5.2% | 8.9% | 9.32% | 3.51% |
| Announcement Date | 3/6/19 | 2/27/20 | 2/26/21 | 3/21/22 | 3/21/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +36.61% | 1.75B | |
| +19.27% | 43.75B | |
| +27.47% | 22.06B | |
| +15.48% | 14.46B | |
| +12.33% | 13.62B | |
| +38.36% | 11.61B | |
| -9.54% | 6.9B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +9.64% | 5.32B |
- Stock Market
- Equities
- A000250 Stock
- Financials Sam Chun Dang Pharm. Co., Ltd
